Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
15th National Conference of the IAOMFP, Chennai, 2006
Abstract
Abstracts from current literature
Acne in India: Guidelines for management - IAA Consensus Document
Addendum
Announcement
Art & Psychiatry
Article
Articles
Association Activities
Association Notes
Award Article
Book Review
Brief Report
Case Analysis
Case Letter
Case Letters
Case Notes
Case Report
Case Reports
Clinical and Laboratory Investigations
Clinical Article
Clinical Studies
Clinical Study
Commentary
Conference Oration
Conference Summary
Continuing Medical Education
Correspondence
Corrigendum
Cosmetic Dermatology
Cosmetology
Current Best Evidence
Current Issue
Current View
Derma Quest
Dermato Surgery
Dermatopathology
Dermatosurgery Specials
Dispensing Pearl
Do you know?
Drug Dialogues
e-IJDVL
Editor Speaks
Editorial
Editorial Remarks
Editorial Report
Editorial Report - 2007
Editorial report for 2004-2005
Errata
Erratum
Focus
Fourth All India Conference Programme
From Our Book Shelf
From the Desk of Chief Editor
General
Get Set for Net
Get set for the net
Guest Article
Guest Editorial
History
How I Manage?
IADVL Announcement
IADVL Announcements
IJDVL Awards
IJDVL AWARDS 2015
IJDVL Awards 2018
IJDVL Awards 2019
IJDVL Awards 2020
IJDVL International Awards 2018
Images in Clinical Practice
In Memorium
Inaugural Address
Index
Knowledge From World Contemporaries
Leprosy Section
Letter in Response to Previous Publication
Letter to Editor
Letter to the Editor
Letter to the Editor - Case Letter
Letter to the Editor - Letter in Response to Published Article
LETTER TO THE EDITOR - LETTERS IN RESPONSE TO PUBLISHED ARTICLES
Letter to the Editor - Observation Letter
Letter to the Editor - Study Letter
Letter to the Editor - Therapy Letter
Letter to the Editor: Articles in Response to Previously Published Articles
Letters in Response to Previous Publication
Letters to the Editor
Letters to the Editor - Letter in Response to Previously Published Articles
Letters to the Editor: Case Letters
Letters to the Editor: Letters in Response to Previously Published Articles
Medicolegal Window
Messages
Miscellaneous Letter
Musings
Net Case
Net case report
Net Image
Net Letter
Net Quiz
Net Study
New Preparations
News
News & Views
Obituary
Observation Letter
Observation Letters
Oration
Original Article
ORIGINAL CONTRIBUTION
Original Contributions
Pattern of Skin Diseases
Pearls
Pediatric Dermatology
Pediatric Rounds
Perspective
Presedential Address
Presidential Address
Presidents Remarks
Quiz
Recommendations
Regret
Report
Report of chief editor
Report of Hon : Treasurer IADVL
Report of Hon. General Secretary IADVL
Research Methdology
Research Methodology
Resident page
Resident's Page
Resident’s Page
Residents' Corner
Residents' Corner
Residents' Page
Retraction
Review
Review Article
Review Articles
Revision Corner
Self Assessment Programme
SEMINAR
Seminar: Chronic Arsenicosis in India
Seminar: HIV Infection
Short Communication
Short Communications
Short Report
Snippets
Special Article
Specialty Interface
Studies
Study Letter
Supplement-Photoprotection
Supplement-Psoriasis
Symposium - Contact Dermatitis
Symposium - Lasers
Symposium - Pediatric Dermatoses
Symposium - Psoriasis
Symposium - Vesicobullous Disorders
SYMPOSIUM - VITILIGO
Symposium Aesthetic Surgery
Symposium Dermatopathology
Symposium-Hair Disorders
Symposium-Nails Part I
Symposium-Nails-Part II
Systematic Reviews and Meta-analyses
Systematic Reviews and Meta-analysis
Tables
Technology
Therapeutic Guideline-IADVL
Therapeutic Guidelines
Therapeutic Guidelines - IADVL
Therapeutics
Therapy
Therapy Letter
View Point
Viewpoint
What’s new in Dermatology
View/Download PDF

Translate this page into:

Net Letter
88 (
3
); 445-445
doi:
10.25259/IJDVL_819_2021
pmid:
35389012

Disseminated and localised herpes zoster following Oxford-AstraZeneca COVID-19 vaccination

Department of Dermatology, Chang Gung Memorial Hospital - Kaohsiung Medical Center, Kaohsiung, Taiwan
Corresponding author: Dr. Lai-San Wong, Department of Dermatology, Chang Gung Memorial Hospital – Kaohsiung Medical Center, Kaohsiung, Taiwan. laisan7@hotmail.com
Licence
This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Jiang ZH, Wong LS, Lee CH, Hsu TJ, Yu YH. Disseminated and localised herpes zoster following Oxford-AstraZeneca COVID-19 vaccination. Indian J Dermatol Venereol Leprol 2022;88:445.

Sir,

Since the emergence of the coronavirus disease 2019 pandemic, vaccination has become crucial to avoid severe complications and achieve herd immunity.1 Two variants of coronavirus disease 2019 vaccine have been approved by the European Medicines Agency: one containing a nucleoside-modified messenger RNA that encodes the viral spike glycoprotein of severe acute respiratory syndrome coronavirus 2, while the other is a viral vector coronavirus disease 2019 vaccine encoding the severe acute respiratory syndrome coronavirus 2 S glycoprotein.2

Herpes zoster, caused by reactivation of the latent varicellazoster virus, is attributed to depressed cell-mediated immunity. This condition frequently affects the elderly due to adaptive immunosenescence.1,3 Known risk-factors include immunosuppressive disease and treatment, which suppress the cell-mediated immunity due to. Recent reports suggest occurrence of herpes zoster in immunocompetent individuals without risk-factors, following the Pfizer (BNT162b2), Moderna (mRNA-1273), Covaxin (BBV152), and AstraZeneca (AZD1222) vaccines against coronavirus disease 2019 [Table 1].4-9

Table 1:: Reported cases of varicella-zoster virus reactivation after coronavirus disease 2019 vaccination
Case series Vaccine type Number of patients 1st dose 2nd dose Gender Age Type of herpes zoster Immune status of patients
Arora et al., 2021 Covaxin 1 1 0 Male: 1 Above 60 years old: 1 Localized Diabetes mellitus: 1
(BBV152) Below 60 years old: 0
Chiu et al., 2021 Moderna 1 1 0 Male: 1 Above 60 years old: 1 Localized Not specified
(mRNA-1273) Below 60 years old: 0
Oxford-AstraZeneca 2 2 0 Male: 2 Above 60 years old: 0 Localized Not specified
(AZD1222) Below 60 years old: 2
Lee et al., 2021 Moderna 14 12 2 Male: 5 Above 60 years old: 7 Localized Diabetes mellitus: 1
(mRNA-1273) Female: 9 Below 60 years old: 7 Crohn’s Disease: 1 Polycythemia Vera treated with ruxolitinib: 1
Pfizer-BioNTech 6 3 3 Male: 5 Above 60 years old: 2 Localized Heart failure: 1
(BNT162b2) Female: 1 Below 60 years old: 4 Kidney failure: 1
Psichogiou et al., Pfizer-BioNTech 7 5 2 Male: 4 Above 60 years old: 5 Localized Prostate cancer: 1
2021 (BNT162b2) Female: 3 Below 60 years old: 2 Heart failure: 1
Fathy et al., 2021 Pfizer-BioNTech 19 27 8 Male: 11 Not specified Localized Diabetes mellitus: 2
(BNT162b2) Female: 24 Median age: 46 Morbid obesity: 2
Moderna 16 Immunodeficiency: 1
(mRNA-1273)
Rodríguez-Jiménez Pfizer-BioNTech 5 3 2 Male: 2 Above 60 years old: 0 Localized Not specified
et al., 2021 (BNT162b2) Female: 3 Below 60 years old: 5
Furer et al., 2021 Pfizer-BioNTech 6 5 1 Male: 0 Above 60 years old: 1 Localized Rheumatic arthritis under
(BNT162b2) Female: 6 Below 60 years old: 5 immunosuppressant: 4 Sjogren’s syndrome under hydroxychloroquine: 1
Anti-phospholipid antibody syndrome: 1

Here, we report three cases of herpes zoster following vaccination with the Oxford-AstraZeneca coronavirus disease 2019 vaccine, and discuss possible patho-mechanisms [Table 2].

Table 2:: Demographic data of patients in our series who developed herpes zoster following Oxford-AstraZeneca coronavirus disease 2019 vaccination
Patient’s data Case 1 Case 2 Case 3
Age 79 91 25
Gender Male Male Female
Comorbidities Late-onset atopic dermatitis Parkinsonism Chronic kidney disease, stage 3 No
Medications Prednisolone 5 mg/day for 1 week pramipexole and levodopa No No
Time interval between vaccination and onset of herpes zoster 4 days after the first dose 3 days after the first dose 7 days after the first dose
Dermatome C7, C8 and T1, then disseminated C7-8 dermatome C3-C4 dermatome
Other symptoms Fever, malaise No No
Treatment for herpes zoster Intravenous acyclovir 800 mg Oral famciclovir 500 mg Oral famciclovir 500 mg Q8H
Q8H for 1 week Q12H for 1 week for 1 week
Previous vaccination for varicella-zoster virus No No No
History of previous herpes zoster No No No
Polymerase chain reaction test of severe acute respiratory syndrome coronavirus 2 Negative Negative Negative

A 79-year-old male presented with painful, vesicular eruptions on his left arm and hand, distributed along the C7, C8, and T1 dermatomes. He had received the first-dose of Oxford-AstraZeneca coronavirus disease 2019 vaccine on the same arm four days before [Figure 1a]. Subsequently, the vesicular eruptions involved his face, chest, back, and extremities over the next three days, and fever was an associated symptom [Figures 1b and 1c]. A systemic review was negative. The patient provided history of varicella without previous herpes zoster episode. He was receiving oral prednisolone (5mg/day) and antihistamines for last one week, along with pramipexole and levodopa for concomitant adult-onset atopic dermatitis and parkinsonism respectively. His baseline blood examination revealed lymphopenia (798 cells/mm3), and the count reduced to 569 cells/mm3 after one-week prednisolone treatment. Serum creatinine, alanine aminotransferase and chest X-ray were normal. Reverse transcription polymerase chain reaction testing for coronavirus disease 2019 was negative. Tzanck smear demonstrated multinucleated giant cells. Serum varicella-zoster virus immunoglobulin G was positive, while immunoglobulin M was negative. We administered intravenous acyclovir 800 mg every 8 h for disseminated herpes zoster. Over the next two days, pustules developed, and pus culture yielded staphylococcus aureus sensitive to amoxycillin. The rash resolved and his clinical condition improved after continuing intravenous acyclovir and amoxycillin/clavulanic acid 1.2 g every 8 h for one week.

Figure 1:: (a) Case 1: A 79-year-old male presented with unilateral vesicular eruptions on his left arm at the dermatome of C7, C8, and T1. (b) Case 1: The vesicles disseminated to face afterward. (c) Case 1: The vesicles spread to back after three days

The other two cases developed their first episode of localised herpes zoster, ipsilateral to the site of vaccination. One was a 91-year-old male who developed left arm swelling three days post first dose of the Oxford-AstraZeneca vaccine. Subsequently, painful vesicular eruptions developed over his left arm (C7-8 dermatome) [Figure 2]. He had a history of stage three chronic kidney disease. The other patient was a 25-year-old female who presented with painful vesicular eruptions over her left neck and shoulder (C3-C4 dermatome) one week after receiving her first dose of the Oxford-AstraZeneca vaccine. There was no history of systemic disease, immunosuppressive condition, recent infection, or stress. A seven-day course of oral famciclovir resolved the lesions in both patients. Neither patient had received the second dose of the Oxford-AstraZeneca vaccine during our follow-up.

Varicella-zoster virus reactivation is reported in 15% and 50% of immunocompetent and immunocompromised patients respectively.10 Disseminated herpes zoster indicates more than twenty skin eruptions outside the primary or adjacent dermatomes.11 It was perceived that immunosuppression is the only risk-factor for disseminated herpes zoster, however, Bollea-Garlatti et al. suggested advanced age to be an independent risk-factor due to adaptive immunosenescence.10

Post-vaccination herpes zoster has been reported following inactivated influenza, hepatitis A, rabies, and Japanese encephalitis vaccines.12 Recently, varicella-zoster virus reactivation following severe acute respiratory syndrome coronavirus 2 BNT162b2 mRNA vaccination has been reported, but the mechanism is unclear. Two of our cases were elderly and susceptible to varicella-zoster virus reactivation. The case with disseminated herpes zoster received prednisolone 5 mg/day for one week to control a flare up of atopic dermatitis. Notably, short-term systemic corticosteroid use is not considered a risk factor for disseminated herpes zoster.13 However, lymphopenia is a known risk factor of varicellazoster virus reactivation, and it might be a contributory factor in our case.14 Both mRNA and adenovirus vector vaccines generate virus-specific T cell responses in blood 2-4 weeks post vaccination.15 However, vaccination against coronavirus disease 2019 may result in some kind of immunomodulation leading to varicella-zoster virus reactivation. Psichogiou et al. suggested that CD8+ cells may not be capable of controlling varicella-zoster virus temporarily due to the massive shift of naïve CD8+ cells towards anti-COVID-19 specific effector CD8+ cells, after Pfizer-BNT162b2 vaccination.1 Furthermore, all our patients developed herpes zoster on the ipsilateral side of vaccination, consistent with literatures.16,17 Though none of our cases received the second dose of their vaccine during our follow-up, van Dam et al. reported two cases who developed herpes zoster following first dose of severe acute respiratory syndrome coronavirus 2 BNT162b2 mRNA vaccine and remained uneventful after second dose.18

We have reported three cases of post-coronavirus disease 2019 vaccination-related herpes zoster We are unable to find any previous report documenting disseminated herpes zoster following Oxford-AstraZeneca vaccination. However, this association could be coincidental. Our report is limited by small sample-size.

This report highlights the need for increased vigilance regarding varicella-zoster virus reactivation after vaccination, especially in the susceptible elderly population as they are prone to suffer from postherpetic neuralgia for a longer period.

Declaration of patient consent

Institutional Review Board (IRB) permission obtained for the study.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.

References

  1. , , , . Reactivation of varicella zoster virus after vaccination for SARS-CoV-2. Vaccines (Basel). 2021;9:572.
    [CrossRef] [PubMed] [Google Scholar]
  2. , , , , , , et al. An Updated review of SARS-CoV-2 vaccines and the importance of effective vaccination programs in pandemic times. Vaccines (Basel). 2021;9:433.
    [CrossRef] [PubMed] [Google Scholar]
  3. , , , . Immunosenescence and human vaccine immune responses. Immun Ageing. 2019;16:25.
    [CrossRef] [PubMed] [Google Scholar]
  4. , , , , , . Herpes zoster following BNT162b2 mRNA COVID-19 vaccination in patients with autoimmune inflammatory rheumatic diseases: A case series. Rheumatology (Oxford). 2021;60:SI90-5.
    [CrossRef] [PubMed] [Google Scholar]
  5. , , , , , , et al. Varicella-zoster virus reactivation after SARS-CoV-2 BNT162b2 mRNA vaccination: Report of 5 cases. JAAD Case Rep. 2021;12:58-9.
    [CrossRef] [PubMed] [Google Scholar]
  6. , , , . 20 post-COVID-19 vaccine-related shingles cases seen at the Las Vegas dermatology clinic and sent to us via social media. J Cosmet Dermatol. 2021;2:1960-4.
    [CrossRef] [PubMed] [Google Scholar]
  7. , , , . Herpes zoster following COVID-19 vaccine: Report of 3 cases. 2021
    [CrossRef] [PubMed] [Google Scholar]
  8. , , , . Herpes zoster after inactivated COVID-19 vaccine: A cutaneous adverse effect of the vaccine. J Cosmet Dermatol. 2021;20:3389-90.
    [CrossRef] [PubMed] [Google Scholar]
  9. , , , , , , et al. Varicella zoster and herpes simplex virus reactivation post-COVID-19 vaccination: A review of 40 cases in an international dermatology registry. 2021
    [CrossRef] [PubMed] [Google Scholar]
  10. , , , , , , et al. Clinical characteristics and outcomes in a population with disseminated herpes zoster: A retrospective cohort study. Actas Dermosifiliogr. 2017;108:145-52.
    [CrossRef] [PubMed] [Google Scholar]
  11. , . Disseminated cutaneous herpes zoster in an immunocompetent elderly patient. Infect Dis Rep. 2014;6:5513.
    [CrossRef] [PubMed] [Google Scholar]
  12. , , , , . Reactivation of herpes virus infections after vaccinations? Lancet. 1999;353:810.
    [CrossRef] [Google Scholar]
  13. , , , , . Short-term efficacy and safety of prednisone in herpes zoster and the effects on IL-6 and IL-10. Exp Ther Med. 2019;18:2893-900.
    [CrossRef] [PubMed] [Google Scholar]
  14. , , , , , . Can COVID-19 increase the risk of herpes zoster? A narrative review. Dermatol Ther (Heidelb). 2021;11:1119-26.
    [CrossRef] [PubMed] [Google Scholar]
  15. , . COVID-19 vaccines: Modes of immune activation and future challenges. Nat Rev Immunol. 2021;21:195-7.
    [CrossRef] [PubMed] [Google Scholar]
  16. , , , , . Ipsilateral zoster ophthalmicus Post COVID-19 vaccine in healthy young adults. Cureus. 2021;13:e16725.
    [CrossRef] [Google Scholar]
  17. , . Ipsilateral herpes zoster after the first dose of BNT162b2 mRNA COVID-19 vaccine. J Eur Acad Dermatol Venereol. 2021;35:e620-2.
    [CrossRef] [PubMed] [Google Scholar]
  18. , , , , , . Herpes zoster after COVID vaccination. Int J Infect Dis. 2021;111:169-71.
    [CrossRef] [PubMed] [Google Scholar]

Fulltext Views
2,308

PDF downloads
133
View/Download PDF
Download Citations
BibTeX
RIS
Show Sections